Metrics as of 10/13/2026, 06:38 PM (Berlin time), refresh in progress.
MiNK Therapeutics Stock
MiNK Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jennifer S. Buell
- Employees
- 15
- Market cap
- $51 M
- IPO
- 15/10/2021
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing…
MiNK Therapeutics stock: price history
1D
-2.8%
1W
-12.6%
1M
-14.7%
6M
-24.3%
YTD
-8.3%
1Y
-27.4%
2Y
+52.5%
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~25% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 15/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about MiNK Therapeutics
Analyst assessment of MiNK Therapeutics
PRICE TARGET LOW
US$35.00
CONSENSUS
US$35.00
MEDIAN
US$35.00
PRICE TARGET HIGH
US$35.00
0
STRONG BUY
4
BUY
1
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 18/05/2026
MiNK Therapeutics stock metrics
P/E
-4.28
P/B
-3.66
EV/EBITDA
-3.52
RETURN ON EQUITY
22.3%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
24.0%
FLOAT SHARES
1,193,954
AVG. DAILY VOLUME (30D)
18,882
Insider transactions (SEC)
Buell Jennifer
Buell Jennifer
Behner Peter
Ryan Barbara
WIINBERG ULF
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about MiNK Therapeutics stock
What does MiNK Therapeutics do?
MiNK Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jennifer S. Buell, the company employs around 15 people.
The IPO was on 15/10/2021; the stock trades on NASDAQ under the ticker INKT.
What do analysts say about MiNK Therapeutics stock?
5 analysts rate the stock, the consensus is Buy (as of 18/05/2026).
The average price target is US$35.00, ranging from US$35.00 to US$35.00, with a median of US$35.00.
This is an external assessment, not a statement by Market Jury.
When does MiNK Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -25% stronger than usual.
Does MiNK Therapeutics pay a dividend?
No, MiNK Therapeutics currently does not pay a dividend.
Which stocks are comparable to MiNK Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get MiNK Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess MiNK Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.